CSBR

Champions Oncology, Inc.

Champions Oncology Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs.

Champions Oncology, Inc. (CSBR) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Value (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
D+
Factor Score 1.8 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B
Factor Score 3.4 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 47.5
EV / EBITDA 182.3
Rev Growth YoY 8.8%
Gross Margin 49.8%
Price Return 3M -4.0%
Price Return 12M -29.5%
Catalyst Signal 0.00
Market Cap $66.1M
TTM Revenue $60.7M
Price / Sales 1.1
ROE -28.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 D+ (1.8) C (2.2) B (3.4) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-04 D+ (1.7) C (2.3) B (3.4) C (2.4) C+ (2.7) C+ (2.5)
2026-10-28 D+ (1.8) C (2.2) B (3.4) C (2.2) C+ (2.7) C (2.4)
2026-10-21 D+ (1.7) C (2.2) B (3.4) C- (2.1) C+ (2.6) C (2.4)
2026-10-14 D+ (1.8) C (2.2) B (3.4) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 8
…